GE Healthcare, Norway, is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
GE Healthcare is the world’s leading supplier of contrast media, used to support patient imaging procedures in 130+ countries globally. All stages of its contrast media manufacturing, from development of Active Pharmaceutical Ingredient (API) to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices.
The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API. Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second.
Continuous improvement of our chemical processes is essential. An important part of this is continuous processing. Over years we have collaborated with Professor Xiong-Wei Ni at Heriot-Watt University on continuous crystallisation, and through this we get involved in the SIMPLI-DEMO project.